Cite as: 562 U. S. ____ (2011)

5

SOTOMAYOR, J., dissenting

“the design” of the countermeasure, §247d–6d(a)(2)(B).
The plain text and structure of the Vaccine Act thus
compel the conclusion that §22(b)(1) pre-empts some—but
not all—design defect claims. Contrary to the majority’s
and respondent’s categorical reading, petitioners correctly
contend that, where a plaintiff has proved that she has
suffered an injury resulting from a side effect caused by
a vaccine’s design, a vaccine manufacturer may invoke
§22(b)(1)’s liability exemption only if it demonstrates that
the side effect stemming from the particular vaccine’s
design is “unavoidable,” and that the vaccine is otherwise
free from manufacturing and labeling defects.3
B
The legislative history confirms petitioners’ interpreta
tion of §22(b)(1) and sheds further light on its pre-emptive
scope. The House Energy and Commerce Committee
Report accompanying the Vaccine Act, H. R. Rep. No. 99–
908, pt. 1 (1986) (hereinafter 1986 Report), explains in
relevant part:
“Subsection (b)—Unavoidable Adverse Side Effects;
Direct Warnings.—This provision sets forth the prin
ciple contained in Comment K of Section 402A of the
Restatement of Torts (Second) that a vaccine manu
facturer should not be liable for injuries or deaths re
sulting from unavoidable side effects even though the
vaccine was properly prepared and accompanied by
proper directions and warnings.
“The Committee has set forth Comment K in this
bill because it intends that the principle in Comment
K regarding ‘unavoidably unsafe’ products, i.e., those
products which in the present state of human skill
and knowledge cannot be made safe, apply to the vac
——————
3 This leaves the question of what precisely §22(b)(1) means by “un
avoidable” side effects, which I address in the next section.

